Breaking Finance News

Maxim Group disclosed SciClone Pharmaceuticals (NASDAQ:SCLN), hiking its price target to $14.00 earlier today

Yesterday SciClone Pharmaceuticals (NASDAQ:SCLN) traded 0.49% higher at $10.25. The company’s 50-day moving average is $9.76 and its 200-day moving average is $11.20. The last stock close price is down -8.46% from the 200-day moving average, compared to the S&P 500 which has decreased -0.03% over the same time. 0 shares of the stock were exchanged, down from an average trading volume of 375,056

Maxim Group bumped up the target of SciClone Pharmaceuticals (NASDAQ:SCLN) to $14.00 stating a possible upside of 0.37%.

See Chart Below

SciClone Pharmaceuticals (NASDAQ:SCLN)

SciClone Pharmaceuticals has a 52 week low of $7.36 and a 52 week high of $15.02 with a P/E ratio of 14.64 The company’s market cap is currently $0.

About SciClone Pharmaceuticals (NASDAQ:SCLN)

SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company's product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company's lead product ZADAXIN (thymalfasin) is approved in approximately 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, the Company markets approximately seven partnered and in-licensed products in China. The Company's development portfolio includes Angiomax, Neucardin, Loramyc, Cleviprex, RapidFilm, VIBATIV and SGX942. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *